Takahiko Murayama
Overview
Explore the profile of Takahiko Murayama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
334
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sasaki N, Homme M, Murayama T, Osaki T, Tenma T, An T, et al.
Mol Cell
. 2024 Dec;
85(4):770-786.e7.
PMID: 39706184
Viral mimicry driven by endogenous double-stranded RNA (dsRNA) stimulates innate and adaptive immune responses. However, the mechanisms that regulate dsRNA-forming transcripts during cancer therapy remain unclear. Here, we demonstrate that...
2.
Murayama T, Mahadevan N, Meador C, Ivanova E, Pan Y, Knelson E, et al.
Cancer Res Commun
. 2024 Aug;
4(9):2399-2414.
PMID: 39177280
Small-cell lung cancer (SCLC) is the most lethal type of lung cancer. Paradoxically, this tumor displays an initial exquisite response to chemotherapy; however, at relapse, the tumor is highly resistant...
3.
Murayama T, Nakayama J, Jiang X, Miyata K, Morris A, Cai K, et al.
Cancer Discov
. 2024 Jan;
14(3):468-491.
PMID: 38189443
Significance: One promising strategy to trigger an immune response within tumors and enhance immunotherapy efficacy is by inducing endogenous "virus-mimetic" nucleic acid accumulation. Here, we identify DHX9 as a viral-mimicry-inducing...
4.
Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets
Murayama T, Gotoh N
Cancer Drug Resist
. 2022 May;
2(3):457-470.
PMID: 35582573
Despite of recent advances in cancer research and development of new anti-cancer drugs, tumor patients' prognoses have not yet been improved well enough. Treatment failure of tumors is highly attributed...
5.
Takeuchi Y, Kimura N, Murayama T, Machida Y, Iejima D, Nishimura T, et al.
Proc Natl Acad Sci U S A
. 2021 Oct;
118(43).
PMID: 34663724
Although it is held that proinflammatory changes precede the onset of breast cancer, the underlying mechanisms remain obscure. Here, we demonstrate that FRS2β, an adaptor protein expressed in a small...
6.
Hirano M, Imai Y, Kaito Y, Murayama T, Sato K, Ishida T, et al.
J Exp Clin Cancer Res
. 2021 Mar;
40(1):110.
PMID: 33757580
Background: Multiple myeloma (MM) is an incurable disease. The acquisition of resistance to drugs, including immunomodulatory drugs (IMiDs), has a negative effect on its prognosis. Cereblon (CRBN) is a key...
7.
Mahadevan N, Knelson E, Wolff J, Vajdi A, Saigi M, Campisi M, et al.
Cancer Discov
. 2021 Mar;
11(8):1952-1969.
PMID: 33707236
Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. SCLC also exhibits cellular plasticity, which could influence its immunobiology. Here we...
8.
Murayama T, Takeuchi Y, Yamawaki K, Natsume T, Li M, Marcela R, et al.
Cancer Sci
. 2020 Dec;
112(3):1209-1224.
PMID: 33340428
Cancer stem-like cells (CSCs) induce drug resistance and recurrence of tumors when they experience DNA replication stress. However, the mechanisms underlying DNA replication stress in CSCs and its compensation remain...
9.
Murayama T, Gotoh N
Cells
. 2019 Jun;
8(6).
PMID: 31226846
Recently, patient-derived xenograft (PDX) models of many types of tumors including breast cancer have emerged as a powerful tool for predicting drug efficacy and for understanding tumor characteristics. PDXs are...
10.
Tominaga K, Minato H, Murayama T, Sasahara A, Nishimura T, Kiyokawa E, et al.
Proc Natl Acad Sci U S A
. 2018 Dec;
116(2):625-630.
PMID: 30587593
Cancer stem-like cells (CSCs) are expanded in the CSC niche by increased frequency of symmetric cell divisions at the expense of asymmetric cell divisions. The symmetric division of CSCs is...